Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | TP53 | P04637 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2928737 | 0.83 | PARP10 (0.51) | MAPTTP53LMNARAB9A | |
| SCHEMBL20518826 | 0.80 | PARP15 (0.54) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL2930089 | 0.80 | MAPT (0.60) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL2928228 | 0.79 | TNKS2 (0.46) | TP53THRBSMN1; SMN2LMNARAB9A | |
| Hydrochloric Acid SCHEMBL10464592 | 0.79 | MAPT (0.47) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL17621008 | 0.77 | THRB (0.44) | MAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL27601944 | 0.74 | MAPT (0.54) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL27706618 | 0.74 | MAPT (0.42) | MAPTTP53THRBSMN1; SMN2LMNA | |
| SCHEMBL3592857 | 0.74 | MAPT (0.42) | MAPTTP53THRBSMN1; SMN2 | |
| SCHEMBL4267704 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691842-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH LLC (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1499622-B1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | WYETH CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1885358-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D ß-LACTAMASES INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-02-13 | — | — | EP | disclosed |
| WO-2007030166-A2 | TRICYCLIC 6-ALKYLIDENE-PENEMS AS CLASS-D β-LACTAMASES INHIBITORS | WYETH (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH (US) | 2006-04-06 | — | — | US | disclosed |
| US-7018997-B2 | Tricyclic 6-alkylidene-penems as β-lactamase inhibitors | WYETH (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1499622-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BETA-LACTAMASE INHIBITORS | Wyeth (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | WYETH | 2004-03-04 | — | — | US | disclosed |
| WO-2003093280-A1 | HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS ΒΕΤΑ-LACTAMASE INHIBITORS | WYETH (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132708-A1 | Process for preparing 6-alkylidene penem derivatives | PGM2, BPGM, MRPL21 | MAPT 3052/4885TP53 2992/4885THRB 3665/4885 |
| US-20060074064-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | MAPT 2034/4885TP53 3728/4885THRB 1339/4885 |
| US-20080318921-A1 | Tricyclic 6-Alkylidene-Penems as Beta-Lactamase Inhibitors | PGLS, MGAM, PREP | MAPT 2034/4885TP53 3728/4885THRB 1339/4885 |
| US-20060276446-A1 | Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors | PEPD, PGLS, MGAM | MAPT 3913/4885TP53 3896/4885THRB 2156/4885 |
| US-20040043978-A1 | Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors | PGLS, MGAM, PREP | MAPT 2074/4885TP53 3602/4885THRB 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.